drugset / Trial / NCT03836885
Apremilast - Oral Lichen Planus Trial
Phase 2
Withdrawn
Sunnybrook Health Sciences Centre
Celgene Corporation · collabSunnybrook Research Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Apremilast for the management of oral lichen planus.
Timeline
- Start
- 2019-11-21
- Primary completion
- 2020-04-22
- Completion
- 2020-04-22
Outcome
Outcome not reported
Stopped (Enrollment): “Study was terminated due to delay in enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 60 mg | Oral |